Market News
Smart Trading. Simplified.
A Rare Opportunity to Turn $1,000 into $461,800
On August 30, 2019, a small firm won a contract from the Pentagon to build a strange new weapon. The Joint Chiefs of Staff calls this new weapon "Unstoppable." This under-the-radar company is not yet a household name.
Our research proves that anyone who gets in now could turn $1,000 into $461,800 >>>
What Happened To John McAfee? A Riches To Rags Story
John McAfee has never been the type of person to follow someone else’s lead. He blazes his own path. That approach to life has led to plenty of—shall we say—interesting events. Once known as a leader in the tech industry, today, it’s more likely that headlines about him focus on his riches to rags story. […]
Profit-Stocks: Upstart Gold Firm Hits High-Grade Gold Zone
In the gold sector, it's the tiny, low-priced exploration firms that typically make the initial discovery through drilling. It's also where investors can secure 10-fold and even 20-fold gains as early drill results are released to the public. Investors are currently jumping into this low-priced gold driller that just hit a high-grade discovery hole in Canada with additional results due any day.
Warren Buffett’s Favorite Way To Invest
Warren Buffett’s Favorite Way To Invest: People pay attention to what the Oracle of Omaha does. As one of the most famous billionaire traders in the world, Warren Buffett has a unique “folksy” appeal to people, especially those who are interested in making money in the markets. “How does he do it?” they ask themselves. […]
Jeff Bezos, Goldman Sachs and a Big Pharma giant have invested billions into this stock.
On August 23, 2018, this small biotech won a patent for a treatment that could help as many as 50 million people...and save the U.S. as much as $20 TRILLION. Jim Cramer says a drug like this would be "The Biggest Drug Ever." And our research shows that anyone who gets in today could turn every $1,000 into $1.1 million.
How High Can Amazon Stock Go?
How High Can Amazon Stock Go? Amazon.com, Inc (NASDAQ:AMZN) is one of the largest companies in the world, valued at over $1.6 trillion. Its founder Jeff Bezos is stepping down as CEO, leaving Andy Jassy at the helm. He’s steering a company that doubled in value at the onset of the pandemic and seemingly hit a […]
Tiny Biotech Creates $2 Trillion Drug
The Wall Street Journal reports new treatment is "transforming medicine."
Bill Gates writes that it could "help humanity."
Ark Investments think it could be a "$2 trillion market."
And one small company owns the patent on it.
This unknown biotech's stock is set to surge 46,751% >>>
Best Investments For Inflation Protection
Which Assets and Investments Do Well In Inflation? During times of high inflation, it’s important to make sure your investment portfolio is structured so as to capitalize on the upside that market-wide rising prices can bring. There are some investments which tend to do better in this environment than others. Here are some of the […]
The World's First $2 Trillion Drug?
The Wall Street Journal reports new treatment is "transforming medicine."
Bill Gates writes that it could "help humanity."
Ark Investments think it could be a "$2 trillion market."
And one small company owns the patent on it.
This unknown biotech's stock is set to surge 46,751% >>>
5 Expensive Stocks Worth Buying
Expensive Stocks Worth Buying: When attempting to establish a diverse investment portfolio, it can be tempting to simply focus on the cheaper stocks in order to create a robust roster of stocks at a relatively low price. While opting for a wide range of low-cost shares might seem like an easy opportunity to kill two […]
Small Biotech Could Soar 1,000%
There's no sector poised to deliver bigger gains in 2021 than small-cap biotech stocks.
In the past year alone...
Novavax Inc jumped from $6.26 to $270.51, a gain of 3,396%.
Aclaris Therapts jumped from $0.70 to $24.28 an increase of 1,583%.
Vaxart Inc rocketed from $0.97 to $14.94, a 1,083% jump.
Here's the next biotech we think could soar 1,000% >>>
View this email online if it doesn't display correctly. This newsletter is not financial advice. Please read our Disclaimer.
To unsubscribe from Financhill, click here.
PO Box 126
Catasauqua, PA 18032
Financhill is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of Financhill are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.
The sender of this email makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity's compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.
The content on any of Financhill websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The Financhill.com educational training program and software services are provided to improve financial understanding.
The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.
Past performance is no guarantee of future performance. This product is for educational purposes only. Practical application of the products herein are at your own risk and Financhill.com, its partners, representatives and employees assume no responsibility or liability for any use or mis-use of the product. Please contact your financial advisor for specific financial advice tailored to your personal circumstances. Any trades shown are hypothetical example and do not represent actual trades. Actual results may differ. Nothing here in constitutes a recommendation respecting the particular security illustrated.
No comments:
Post a Comment